A. Fagiolini

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
A Fagiolini, A. Fagiolini, Andrea Fagiolini, Andrea M Fagiolini
Publication record
461 papers · 14,411 citations · H-index 63

PAPERS

Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder.
202517 citationsauthor #3
Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With Schizophrenia
20239 citationsauthor #20
Clinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder
202311 citationsauthor #6
Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
202321 citationsauthor #5
Exploratory study of ultraviolet B (UVB) radiation and age of onset of bipolar disorder
20230 citationsauthor #44
Delphi Panel on the Dimensions and Assessment of Functional Recovery in First-Episode and Early-Phase Schizophrenia Patients
20230 citationsauthor #5
Autistic traits distribution in different psychiatric conditions: A cluster analysis on the basis of the Adult Autism Subthreshold Spectrum (AdAS Spectrum) questionnaire.
202314 citationsauthor #16
Exploring depression in Parkinson’s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management
20238 citationsauthor #5
Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery
202321 citationsauthor #2
Vulnerabilities in Mental Health due to Covid-19 Pandemic: The Response of the Italian Physicians
20237 citationsauthor #10
Treating major depressive disorder with mixed features.
20238 citationsauthor #1
Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic
20238 citationsauthor #2
Does social cognition change? Evidence after 4 years from the Italian Network for Research on Psychoses
20239 citationsauthor #17
Exploring depression in Alzheimer’s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management
202313 citationsauthor #5
Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder
202316 citationsauthor #1
Role of trazodone in treatment of major depressive disorder: an update
202336 citationsauthor #1
Family functioning and personal growth in Italian caregivers living with a family member affected by schizophrenia: Results of an add-on study of the Italian network for research on psychoses
20236 citationsauthor #13
Sex and gender differences in clinical and functional indices in subjects with schizophrenia and healthy controls: Data from the baseline and 4-year follow-up studies of the Italian Network for Research on Psychoses.
202310 citationsauthor #15
Prevalence study of mental disorders in an Italian region. Preliminary report
202314 citationsauthor #11
Delphi Panel on the Relationship Between Long-Acting Injectable Antipsychotics and Longer-Term Functional Recovery in First-Episode and Early-Phase Schizophrenia Patients
20230 citationsauthor #5
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
2022119 citationsauthor #5
Radiofrequency echographic multispectrometry (REMS): an innovative technique for the assessment of bone status in young women with anorexia nervosa
202219 citationsauthor #6
Treatment persistence with aripiprazole once monthly: a 4-year follow-up
20220 citationsauthor #1
Clinical evaluation of switching from immediate‐release to prolonged‐release lithium in bipolar patients, poorly tolerant to lithium immediate‐release treatment: A randomized clinical trial
202210 citationsauthor #5
Emotional blunting in patients with depression. Part I: clinical characteristics
202237 citationsauthor #3
Effectiveness and Tolerability of Supratherapeutic Dosing of Vortioxetine in Patients With Treatment-Resistant Depression.
20221 citationsauthor #6
Effectiveness of light therapy as adjunctive treatment in bipolar depression: A pilot study.
20225 citationsauthor #9
Intravenous valproic acid for the treatment of inpatients with bipolar disorder experiencing manic or depressive episodes with mixed features
20220 citationsauthor #5
Clinical and psychological factors associated with resilience in patients with schizophrenia: data from the Italian network for research on psychoses using machine learning
20224 citationsauthor #16
Emotional blunting in patients with depression. Part III: relationship with psychological trauma
20228 citationsauthor #3
Association between polarity of first episode and solar insolation in bipolar I disorder.
202215 citationsauthor #44
QTc interval diurnal variations in patients treated with psychotropic medications: implications for the evaluation of drug induced QTc changes
20223 citationsauthor #6
Efficacy and tolerability of intravenous citalopram for the treatment of depression and anxiety in patients with mood disorders
20220 citationsauthor #2
Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis
20223 citationsauthor #2
Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and efficacy (REAL-ESK study).
2022104 citationsauthor #3
Delphi panel on management, treatment goals and functional recovery with long-acting injectable antipsychotics in first episode and early phase schizophrenia
20220 citationsauthor #2
Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice
202216 citationsauthor #13
Mental health in Italy after two years of COVID-19 from the perspective of 1281 Italian physicians: looking back to plan forward
20229 citationsauthor #9
Treatment persistence in patients with schizophrenia treated with lurasidone in Italian clinical practice
20226 citationsauthor #1
Emotional blunting in patients with depression. Part II: relationship with functioning, well-being, and quality of life
202215 citationsauthor #3
Exploration of mood spectrum symptoms during a major depressive episode: The impact of contrapolarity—Results from a transdiagnostic cluster analysis on an Italian sample of unipolar and bipolar patients
202210 citationsauthor #10
The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management
2022133 citationsauthor #7
Evolution of antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia in the real-life: A 4-year follow-up naturalistic study.
202210 citationsauthor #17
Heterozygosity for neuronal ceroid lipofuscinosis predisposes to bipolar disorder
20224 citationsauthor #10
Editorial: Assessment and diagnosis of bipolar disorder: Volume II
20220 citationsauthor #1
Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
20223 citationsauthor #5
Emotional blunting in patients with depression. Part IV: differences between patient and physician perceptions
20229 citationsauthor #3
Neuroticism and Conscientiousness Moderate the Effect of Oral Medication Beliefs on Adherence of People with Mental Illness during the Pandemic
202210 citationsauthor #16
Treating bipolar disorder with most recent episode depressed with mixed features with intravenous trazodone
20220 citationsauthor #9
Impact of menstrual cycle events on bipolar disorder course: a narrative review of current evidence
202212 citationsauthor #2
Pocket Guide to Practical Psychopharmacology: Lithium and Anticonvulsants in Psychiatric Practice
20221 citationsauthor #1
P.0100 Impact of emotional blunting on functioning in patients with MDD: do the perspectives of patients and HCPS differ?
20210 citationsauthor #3
Factors associated with lifetime suicide attempts in bipolar disorder: results from an Italian nationwide study
202113 citationsauthor #4
Treatment of Agitation With Lorazepam in Clinical Practice: A Systematic Review
202113 citationsauthor #3
A new approach for seasonal pattern: is it related to bipolarity dimension? Findings from an Italian multicenter study
20217 citationsauthor #12
Which mixed depression model? A comparison between DSM‐5‐defined mixed features and Koukopoulos' criteria
20218 citationsauthor #11
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials
2021165 citationsauthor #13
P.0091 Effect of medical education on psychiatrists’ knowledge, competence and confidence in management of major depressive disorder
20210 citationsauthor #5
Autism spectrum in patients with schizophrenia: correlations with real-life functioning, resilience, and coping styles
202113 citationsauthor #11
Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review
20216 citationsauthor #18
Physical Activity Monitoring Preferences in Adults With Bipolar Disorder
20211 citationsauthor #5
Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment
202131 citationsauthor #5
Are anxiety disorders associated with accelerated ageing and cognitive decline? A multicenter italian study in middle aged and older patients and controls
20210 citationsauthor #4
Accuracy of self-assessment of real-life functioning in schizophrenia
202121 citationsauthor #84
Effectiveness of Intramuscular Chlorpromazine for Rapid Treatment of Psychomotor Agitation: A Naturalistic, Retrospective, and Observational Study.
20211 citationsauthor #9
Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study
202122 citationsauthor #4
[Delirium in the "young" covid-19 patient (<65 years): preliminary clinical indications].
20210 citationsauthor #9
Corrigendum to "Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action [European Neuropsychopharmacology (2020) 36, 121-136]".
20211 citationsauthor #5
DSM-5 and ICD-11 criteria for bipolar disorder: Implications for the prevalence of bipolar disorder and validity of the diagnosis - A narrative review from the ECNP bipolar disorders network.
202140 citationsauthor #3
Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting.
202121 citationsauthor #2
Investigating the Relationship between Autistic Traits, Ruminative Thinking, and Suicidality in a Clinical Sample of Subjects with Bipolar Disorder and Borderline Personality Disorder
202141 citationsauthor #9
Biomarkers, Inflammation, and Bipolar Disorder: Association Between the Improvement of Bipolar Disorder Severity and the Improvement in C-Reactive Protein Levels After 7 Days of Inpatient Treatment
20218 citationsauthor #7
Treatment Persistence and Real- World Effectiveness of Aripiprazole Once Monthly: A Four-Year Follow-Up
20210 citationsauthor #1
[Lamotrigine in bipolar disorder: preventing depression to treat the disease].
20211 citationsauthor #4
[Theory of mind in bipolar disorder: a review].
20210 citationsauthor #6
Variations in seasonal solar insolation are associated with a history of suicide attempts in bipolar I disorder
202126 citationsauthor #46
Call to action regarding the vascular‐bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders
202091 citationsauthor #6
A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder
202021 citationsauthor #1
Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin.
202046 citationsauthor #14
Unmet Needs in the Assessment and Treatment of Psychomotor Agitation
20201 citationsauthor #6
P.454 Use of chlorpromazine in the treatment of psychomotor agitation: efficacy, tolerability and safety. A pilot study
20200 citationsauthor #7
Predictors of Depressive Switch in Patients With Bipolar I Disorder Who Initiated or Changed Pharmacologic Treatment for Mania or Mixed-Mania: A Prospective Observational Study.
20205 citationsauthor #5
Eating disorders and autism spectrum: links and risks
202068 citationsauthor #4
EPA volume 63 issue S1 Front cover and matter
20200 citationsauthor #3
Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance
202066 citationsauthor #3
COVID-19 Diary From a Psychiatry Department in Italy.
202078 citationsauthor #1
Practical prescribing with COVID-19 medications and psychotropics: a guide to pharmacokinetic interactions
20200 citationsauthor #6
Mood spectrum symptoms during a major depressive episode: Differences between 145 patients with bipolar disorder and 155 patients with major depressive disorder. Arguments for a dimensional approach
202010 citationsauthor #10
Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
202083 citationsauthor #1
Advances in treatment for postpartum major depressive disorder
20208 citationsauthor #10
Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations
202075 citationsauthor #9
Lithium and suicide prevention in mood disorders and in the general population: A systematic review.
202084 citationsauthor #12
Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches
202028 citationsauthor #4
The influence of autistic symptoms on social and non-social cognition and on real-life functioning in people with schizophrenia: Evidence from the Italian Network for Research on Psychoses multicenter study
202039 citationsauthor #82
Correction to: Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations
20203 citationsauthor #9
[Personalized medicine with extended-release trazodone and/or once-a-day trazodone: from research trials to clinical practice].
20201 citationsauthor #4
Psychomotor agitation and hyperactive delirium in COVID-19 patients treated with aripiprazole 9.75 mg/1.3 ml immediate release
202016 citationsauthor #12
Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives
20208 citationsauthor #3
The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder
202055 citationsauthor #11
Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action.
202018 citationsauthor #8

TIMELINE

1994 4 citations

1998 22 citations

1999 341 citations

2000 230 citations

2001 16 citations

2002 856 citations

2003 536 citations

2004 414 citations

2005 1,458 citations

2006 493 citations

2007 199 citations

2008 1,629 citations

2009 904 citations

2010 302 citations

2011 125 citations

2012 544 citations

2013 406 citations

2014 777 citations

2015 312 citations

2016 666 citations

2017 571 citations

2018 390 citations

2019 945 citations

2020 1,034 citations

2021 439 citations

2022 566 citations

2023 211 citations

2025 17 citations

Unknown 36 citations

A. Fagiolini

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT